4D Molecular Therapeutics and MedImmune Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease

MedImmune, the global biologics research and development arm of
AstraZeneca, and 4D Molecular Therapeutics (4DMT), a world-leader in
Therapeutic Vector Evolution for adeno-associated virus (AAV) gene
therapy vector discovery and product development, today announced a
collaboration to develop and commercialize a gene therapeutic for
patients with chronic lung disease, utilizing 4DMT’s novel discovery
platform to generate optimized AAV vectors.

AAV vectors are a leading delivery vehicle for transporting genes to
accessible tissues in the body for in-vivo expression and therapeutic
application. They target both dividing and nondividing cells without
integrating genetic material into the host genome. The genetic material
transferred by AAV vectors into cells is the blueprint for the
production of a protein whose function targets pathological processes
contributing to diseases.

The collaboration will leverage 4DMT’s expertise in vector discovery and
engineering, optimization and process development. MedImmune will
conduct product development beginning from early clinical stages,
drawing on the company’s extensive expertise in respiratory science.

Roland Kolbeck, Vice President, Research & Development Respiratory,
Inflammation and Autoimmunity at MedImmune, said: “Rapid advances in AAV
therapy make this a promising tool to advance innovation in chronic lung
disease, particularly in areas of high unmet need. This collaboration
strategically pairs 4DMT’s expertise in AAV with MedImmune’s leadership
in respiratory science, focused on early intervention and disease
modification.”

David Kirn MD, CEO and co-founder of 4DMT, added: “This exciting
collaboration may open the door to significant advancements in treatment
for respiratory patients. Our progress in customized AAV vectors enables
us to unlock the potential of gene therapy and, with MedImmune’s
expertise in protein engineering, we will continue to push boundaries in
proprietary gene delivery to tissues and cells.”

About MedImmune

MedImmune is the global biologics research and development arm of
AstraZeneca, a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialization of small
molecule and biologic prescription medicines. MedImmune is pioneering
innovative research and exploring novel pathways across Oncology,
Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection
and Vaccines. The MedImmune headquarters is located in Gaithersburg,
MD., one of AstraZeneca’s three global R&D centres, with additional
sites in Cambridge, UK and South San Francisco, CA. For more
information, please visit www.medimmune.com.

About 4D Molecular Therapeutics (4DMT)

4DMT is focused on the discovery and development of targeted, customized
and proprietary next-generation AAV gene therapy products for use in
patients with severe genetic diseases with high unmet medical need. Our
robust discovery platform, termed Therapeutic Vector Evolution, empowers
us to create customized gene delivery vehicles to deliver genes
specifically to any tissue or organ in the body, by optimal clinical
routes of administration, at manageable doses and with resistance to
pre-existing antibodies. These proprietary and targeted products allow
us to treat both rare genetic diseases and complex large market
diseases. 4DMT is creating a diverse and deep product pipeline through
its own internal 4D products, as well as partnered programs.

About 4DMT’s Therapeutic Vector Evolution

4DMT is advancing the field of targeted and optimized AAV vector
technology by deploying principles of evolution and natural selection to
create vectors that efficiently and selectively target the desired cells
within the diseased human organ via clinically optimal routes of
administration, at manageable doses and with resistance to pre-existing
antibodies in the population. Our Therapeutic Vector Evolution platform
deploys over 100 million unique AAV variants from over 35 unique and
proprietary 4DMT AAV libraries with extensive diversity. After defining
the Target Product Profile, and the associated Target Vector Profile,
4DMT then applies proprietary methods to identify lead vectors from
within our AAV libraries. The result is a customized, novel, and
proprietary pharmaceutical-grade product uniquely designed for targeted
therapeutic gene delivery and efficacy in humans.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005214/en/

Leave a Comment